PhytoMedical Technologies

David Phillips at 10Q Detective is unimpressed with PhytoMedical Technologies (PYTO.OB):

The 10Q Detective suggests that if PhytoMedical Technologies really wants to be taken seriously by the investment community—Perchance the Company could design a clinical trial that examines the safety and efficacy on the potential appetite-stimulating properties of a well-known plant-derived compound on the cachexia of cancer, HIV/AIDS symptomatology, and other wasting syndromes. This medicinal plant is called, cannabis sativa.
To be blunt (BA!)—given the Company’s current fundamental outlook—one would have to be smoking cannabis daily to even consider buying this stock.

I guarantee you’ll never read that in a Merrill research report.

Posted by on February 27th, 2006 at 10:06 pm

The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment. I or my affiliates may hold positions or other interests in securities mentioned in the Blog, please see my Disclaimer page for my full disclaimer.